+ Follow DISEASE COOPERATIVE STUDY Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1421362
[Title] => Vitamin E may slow functional decline in Alzheimer’s
[Summary] => High-dose vitamin E significantly slowed functional decline over two years in a population of patients with mild-moderate Alzheimer’s disease. Compared with placebo, 2,000 IU daily vitamin E reduced progression by 19% per year, colleagues wrote.
[DatePublished] => 2015-02-08 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[1] => Array
(
[ArticleID] => 209261
[Title] => NSAIDs for one year failed to show Alzheimer’s disease
[Summary] => Neither the selective cyclooxygenase-2inhibitor rofecoxib nor the nonselective NSAID naproxen slowed the rate of cognitive or functional decline in a one-year, placebo-controlled study of patients with Alzheimer’s disease, it was reported at the Eighth International Conference on Alzheimer’s disease and Related Disorders.
[DatePublished] => 2003-06-08 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
)
)
DISEASE COOPERATIVE STUDY
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1421362
[Title] => Vitamin E may slow functional decline in Alzheimer’s
[Summary] => High-dose vitamin E significantly slowed functional decline over two years in a population of patients with mild-moderate Alzheimer’s disease. Compared with placebo, 2,000 IU daily vitamin E reduced progression by 19% per year, colleagues wrote.
[DatePublished] => 2015-02-08 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[1] => Array
(
[ArticleID] => 209261
[Title] => NSAIDs for one year failed to show Alzheimer’s disease
[Summary] => Neither the selective cyclooxygenase-2inhibitor rofecoxib nor the nonselective NSAID naproxen slowed the rate of cognitive or functional decline in a one-year, placebo-controlled study of patients with Alzheimer’s disease, it was reported at the Eighth International Conference on Alzheimer’s disease and Related Disorders.
[DatePublished] => 2003-06-08 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
)
)
abtest
